Missing Script

Get updates

MS-N121 · Supportive care · Human evidence · Appraised 24 October 2026

Can transcutaneous electrical acupoint stimulation (TEAS) reduce acute pain after same-day lung cancer surgery?

Evidence at a glance

  • Evidence label: Large short-term signal from one small trial; replication needed
  • Benefit: A single-center sham-controlled trial reported markedly lower pain during the first 24 hours after thoracoscopic wedge resection.
  • Certainty: Low-to-moderate confidence because the effect was unusually large, follow-up was brief and independent replication is absent.
  • Risk: Noninvasive stimulation was not linked to more adverse events in the trial, but electrode placement and device precautions still matter.

What was studied

Population and design: 100 adults with ASA physical status I–II undergoing video-assisted thoracoscopic wedge resection at one Shanghai hospital.

Studied regimen: Thirty minutes of electrical stimulation at LI4 and PC6 in the recovery unit versus sham stimulation.

What the evidence found

Mean visual-analogue pain scores were 0.94 versus 1.84 at 1 hour, 2.00 versus 5.40 at 12 hours and 1.72 versus 4.02 at 24 hours. Moderate-to-severe pain within 12 hours was reported in 12% versus 74%; analgesic use was also lower. Quality-of-recovery score at 24 hours was 130.8 versus 115.9. Postoperative nausea/vomiting, length of stay and adverse-event rates did not differ.

How to interpret it

The very large effect in a small, single-center study should be treated cautiously until reproduced. Blinding to active sensation can be difficult. Outcomes stop at 24 hours; there is no evidence here about longer recovery, chronic pain or cancer control.

Practical safety context

The trial reported no between-group difference in adverse events. TEAS is noninvasive, but it should not be placed over broken or infected skin, used near implanted electronic devices without clearance, or substituted for assessment of severe postoperative pain, bleeding, breathlessness or other complications.

Questions for the care team

  • Is the symptom or complication being caused by something that needs conventional treatment first?
  • Would blood counts, anticoagulants, infection risk, surgery, radiation effects or implanted devices change whether this is safe?
  • What outcome will we track, and when should we stop if it is not helping?

Funding and conflicts

Funding and conflict details were reported in the full article; no product efficacy beyond the tested device and protocol can be inferred.

Sources

Last literature search: 24 October 2026. Record appraisal: 24 October 2026. This page is educational and does not replace individualized medical advice. Symptom improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.